昨年１１月、「Biopta Limited」の買収発表時に「BioSpectrum」(２０１５年１１月２６日付）に掲載された
Dr David Bunton(Biopta CEO)のコメントを以下に紹介します。
英語原文で恐縮です。
[Dr David Bunton,Biopta's co-Founder and CEO said,"The acquisition by ReproCELL is a great
opportunity to build on the solid platform we have in outsourced drug discovery services.
Scotland is known for the quality of its scientists and customer service and ReproCELL's investment
recognizes these strengths.
We have had a close partnership with BioServe, another ReproCELL Group company, for the past five years,which has helped us establish a very successful US subsidiary. We see the acquisition as the natural next step in the growth of the UK and US business."]
昨年１１月、「Biopta Limited」の買収発表時に「BioSpectrum」(２０１５年１１月２６日付）に掲載された
Dr David Bunton(Biopta CEO)のコメントを以下に紹介します。
英語原文で恐縮です。
[Dr David Bunton,Biopta's co-Founder and CEO said,"The acquisition by ReproCELL is a great
opportunity to build on the solid platform we have in outsourced drug discovery services.
Scotland is known for the quality of its scientists and customer service and ReproCELL's investment
recognizes these strengths.
We have had a close partnership with BioServe, another ReproCELL Group company, for the past five years,which has helped us establish a very successful US subsidiary. We see the acquisition as the natural next step in the growth of the UK and US business."]